Deep brain stimulation (DBS) is a surgical neuromodulation procedure with a historically wide range of possible therapeutic indications, including movement disorders, neuropsychiatric conditions, and cognitive disorders. Ongoing research in this field is critical to gain further insights into the mechanisms of DBS, to discover novel brain targets for new and existing indications, and to refine targeting and post-operative programming techniques for the optimization of therapeutic outcomes.
INTRODUCTION
Deep brain stimulation (DBS) is a neurosurgical intervention that involves the placement of electrodes within the brain in order to electrically stimulate specific targets and thereby modulate dysregulated neural circuitry [1] . Given its relative safety, therapeutic efficacy, and reversible and adjustable nature, DBS has become a mainstream surgical procedure over the last three decades. To date, it is estimated that over 150,000 patients have been implanted at over 700 centers worldwide [2] . While DBS is most often employed as a treatment for movement disorders such as Parkinson's disease and essential tremor, it is increasingly being examined for its therapeutic potential across a range of neuropsychiatric and cognitive disorders, as well as for conditions such as neuropathic pain and epilepsy [3] .
The growing demand for minimally-invasive approaches to neurological disorders and refractory neuropsychiatric conditions has boosted interest in neuromodulatory approaches such as DBS.
As the field continues to expand, well-designed and executed clinical trials are needed as they are the pinnacle of evidence that will shape the practice of DBS. Progress in the field may be impeded by our limited understanding of the mechanism(s) of action of DBS, underutilization of adjuncts such as imaging, and by the constraints of regulatory considerations. The analysis of trends of past and current clinical trial landscapes can elucidate some of these challenges and provide insights into better/novel target selection, multi-modal planning, and improved stimulation parameter choices and ultimately, the optimization of therapeutic outcomes. 6/25 
METHODS AND MATERIALS
A comprehensive search for past and ongoing clinical trials pertaining to DBS was conducted using the publicly available trial registry, ClinicalTrials.gov (https://clinicaltrials.gov/). This search was conducted in January of 2019 and included the search terms, 'deep brain stimulation' OR 'DBS'. Identified clinical trial entries were screened to ensure they pertained to DBS, with relevant trials retained for further analysis. Trial start date, study completion status, clinical phase, projected subject enrollment, and funding source were recorded as posted in trial entries.
Treatment condition was captured according to the specific disorder(s) described in each trial's entry and subsequently broadly categorized as either 'movement disorder', 'psychiatric disorder', 'cognitive disorder', 'epilepsy', 'pain', or 'other'. Brain target for electrode insertion was also recorded as posted in trial entries and grouped into more general categories where appropriate.
To account for studies that specified multiple targets, each individual target was enumerated; accordingly, these multiple-target studies were double-counted for the analysis of targets. The country of origin was determined according to the country of the responsible party (i.e., the lead center in multi-center studies). Device manufacturer was captured by noting any mention of specific manufacturer's DBS hardware or relationship with a specific manufacturer in the trial entry. Depending on whether or not an intervention/treatment was being evaluated, study design was classified as 'interventional' (e.g., study determining the efficacy of novel brain targets) or 'non-interventional' (e.g., study examining imaging or neurophysiological changes). Finally, study topic was examined with reference to whether trials were described as involving 'imaging' (e.g., CT, MRI, PET) or 'electrophysiology' (e.g., single-unit recordings, local field potentials, EEG, MEG) in any capacity beyond standard clinical practice. Where applicable, 'rate of 7/25 change' metrics were calculated in order to examine how rapidly new clinical trials of different classes, purposes, or origins were being generated.
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RESULTS
Our search of the ClinicalTrials.gov database generated an initial list of 426 registered clinical trials. Following screening for pertinence to DBS, a total of 384 entries were identified, a count that included active trials as well as those that have already been completed or suspended, terminated, or withdrawn. The registration date for these trials ranged from 2019 back to the creation of the ClinicalTrials.gov database following the Food and Drug Administration Modernization Act of 1997.
Studies by start date and status of completion
Approximately half of all studies commenced within the last five years ( Fig. 1A ). All studies that began in the late 1990s and early 2000s have at this point either been completed or terminated.
The oldest clinical trial that was still listed as actively recruiting started in 2006 and is an interventional study evaluating the efficacy of DBS of the subgenual cingulate white matter for treatment-resistant depression. Of the 327 trials (85.2% of all trials) with a known status of completion, most were either already completed (42.2%) or actively recruiting (35.5%). A considerable portion of trials -over 10% in total -were listed as either withdrawn (5.8%), terminated (4.6%), or suspended (0.6%). With regards to the projected trial duration, the mean length of a DBS-related clinical trial was found to be 48.4 ± 1.9 months (SEM). The maximum and minimum projected trial length were 194 months (for a study recruiting for N = 300 9/25 subjects) and 2 months (for 4 studies with between N = 2 and N = 26 subjects, 2 of which were completed, one of which was withdrawn, and one of which was terminated), respectively.
Studies by phase and projected enrollment
For the 384 clinical trials identified, projected enrollment ranged from 1-10 subjects (33.3% of trials) to >500 subjects (1.6%), with an enrollment of 11-50 subjects being most common (43.8%). Studies enrolling 51-100 subjects and 101-500 subjects accounted for 7.8% and 8.1% of trials, respectively, while 5.5% of trials did not provide enrollment information. Information regarding the study phase was found to be lacking, with 72.1% of trial entries omitting this information. Of the 107 studies (27.9% of all trials) that specified phase, Phase I studies were most common (45.8% of trials), followed sequentially by Phase II (27.1%), Phase III (16.8%), and Phase IV (10.3%). Figure 2 shows the relationship between phase and projected enrollment numbers for the 106 trials (27.6% of all trials) that provided information on both these aspects.
Studies by clinical disorder
Registered clinical trials studied a total of 28 different conditions (Table 1 ). Over half of registered DBS-related clinical trials pertained to movement disorders (62.0%) ( Fig. 3A) .
Clinical trials for psychiatric disorders accounted for 23.7% of studies, followed by cognitive disorders (4.7%), epilepsy (3.4%), and pain (1.8%). The number of new trials registered per year 10/25 for movement, psychiatric, and cognitive disorders has increased from 3.0, 1.3, and 0.1 (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) ) to 17.9, 6.9, and 1.6 (2008-2018), respectively ( Fig. 3B , Supplementary Table 1 ). Some of the more novel indications described, each with a total of 3 studies, include Huntington's disease, post-traumatic stress disorder, schizophrenia, and decreased level of consciousness/coma.
Studies by brain target
From the 384 studies listed since 1997, 26 distinct brain targets were identified ( Table 2 ). 57% of brain areas targeted in registered clinical trials were subcortical components of the cortico-basal ganglia-thalamo-cortical motor circuit. The most frequent target overall was the subthalamic nucleus (STN) or neighboring posterior subthalamic area (33% of all trials collectively), followed by the globus pallidus pars internus (GPi) (12%). Affective limbic structures such as ventral striatum/ventral capsule (VS/VC), anterior limb of the internal capsule (ALIC), and subgenual cingulate were the next most frequently engaged group of targets, while memoryimplicated structures like the fornix and nucleus basalis occupied the third-largest group, collectively ( Table 2 ). Single studies that examined more novel targets include the putamen for the treatment of Parkinson's disease, hippocampus for refractory epilepsy, periventricular/periaqueductal grey for pain and autonomic dysreflexia, and the dentatorubrothalamic tract for essential tremor.
A considerable number of trials used multiple electrodes to target different structures or used a single electrode to stimulate more than one structure. Of these multi-target trials, 46 trials listed 11/25 two different targets and 9 trials listed three or more targets. Notably, only 15 multi-target trials were registered between 1997 and 2010, while 40 were registered between 2011 and 2019.
Interesting multi-target studies that used a single electrode to stimulate multiple structures include the targeting of the STN and nucleus basalis of Meynert (NBM) for the treatment of Parkinson's disease with dementia, and the STN and substantia nigra (SN) for resistant freezing of gait and dysphagia in Parkinson's disease.
Studies by country of origin
By country of study origin, the top five countries that accounted for the highest percentage of trials include the USA (41.9%), France (14.8%), China (8.9%), Germany (6.8%), and Canada (6.5%) ( Fig. 4A , Table 3 Studies by manufacturer and funding source 12/25 Out of the 384 studies identified, 157 (40.9% of all trials) listed a manufacturer. Two-thirds of these studies used Medtronic PLC DBS systems (68.8%); by comparison, the second (Boston Scientific Corp.) and third (Abbott Laboratories, formerly St. Jude Medical, Inc.) largest manufacturers by clinical trial support accounted for 10.2% and 7.6% of trials, respectively (Fig.   5A ). A breakdown by the year of the study's start date shows the cumulative growth in the number of studies using a certain manufacturer, from 1997-2018 (Fig. 5B ). The number of new trials started per year are listed in Supplementary Table 3 . Close to a quarter (24.2%) of clinical trials were noted to be funded by industry. The remaining trials (75.8%) were funded by nonindustry sources such as the government (e.g., NIH).
Studies by design and primary topic
In order to survey the principal content and design of identified clinical trials, all 384 studies were first classified as either interventional (78.4%) or non-interventional (21.6%). Of the 301 interventional studies that provided information about randomization design, approximately half were found to be randomized (48.2%) and the other half non-randomized (50.8%). 15 
DISCUSSION
We identified and categorized 384 past and present publicly registered clinical trials pertaining to DBS. The number of registered clinical trials has grown rapidly since the ClinicalTrials.gov database was first introduced, indicating that human DBS-related research is a rapidly growing field.
Current trends and future directions
Our analyses on DBS-related clinical trials revealed many interesting trends. With regard to country of origin, the United States has conducted the greatest number of DBS trials of any country to date by a notable margin. France has the second-highest number of registered clinical trials, followed by China, Germany, and Canada.
While China has historically lagged behind Western countries in the development of DBS, this appears to be changing. It has been suggested that factors contributing to the lower volume of DBS in China in the past include lack of health insurance, high out-of-pocket costs, and limited resources [4, 5] . Despite the absence of DBS trials up until 2010, China's rate of trials per year has rapidly increased to place it amongst the top three DBS trials contributors, above Germany and Canada. DBS has quickly evolved in China, perhaps in part due to the establishment of local manufacturing capacity that decreases the high costs of hardware -a major obstacle in DBS implantation [6] . It is interesting to note that although China's first DBS surgery was only 14/25 performed in 1998 on a PD patient [7] , the country is now leading trials on novel indications for DBS such as drug addiction [8, 9] .
As expected, movement disorders DBS -which has been FDA-approved for over two decades (i.e., essential tremor in 1997, PD in 2002, dystonia in 2003 [10] [11] [12] ) -constitutes the largest clinical research focus in the field. Befitting the more established nature of this indication, movement disorder trials tend to investigate quality of life outcomes, economic benefit, and novel DBS parameters to optimize therapy as opposed to assessing the safety and efficacy of novel brain targets [13] [14] [15] . It is notable that, although movement disorders accounted for over 60% of registered trials, they represent a considerably larger share (we estimate at >90% of DBS surgeries), suggesting that current clinical research is in fact disproportionately focused on experimental indications and not on established treatments. Psychiatric and cognitive indications account for the second and third largest area of active trials, respectively, reflecting their progressively later entry onto the DBS stage.
The distribution of brain targets reflects the same pattern as that of the disorders given their close association. Key subcortical hubs of the cortico-basal ganglia-thalamo-cortical motor circuits, such as the STN, GPi, and motor thalamus, are collectively targeted by half of all studies.
Structures implicated in affective (e.g., VS/VC, ALIC, subgenual cingulate) and cognitive (e.g., fornix, nucleus basalis) limbic circuitry account for smaller but still sizeable proportions of the total body of clinical trials. It is important to note that, in many cases, multiple targets have been explored for single indications. Major depressive disorder, for instance, has been addressed using at least five different brain targets, including the subgenual cingulate, VS/VC, inferior thalamic 15/25 peduncle, medial forebrain bundle (MFB), and bed nucleus of stria terminalis (BNST) [16] .
Some of these targets were identified via unanticipated results observed during other DBS studies. The VS/VC became a target for depression as a result of improved mood in OCD patients who underwent VC/VS DBS [17] . In another example, hypothalamic DBS intended to treat obesity resulted in memory enhancement, which led to the emergence of forniceal DBS for Alzheimer's disease [18] .
Our results also highlight the growing popularity of multi-target studies, a trend that may be driven in part by advances in imaging-guided targeting [19] and electrode technology, such as the development of longer, dual-frequency electrodes [20] and the recent advent of directional leads [21, 22] . A multi-target strategy may be promising for complex disorders that involve symptoms with different pathogenic mechanisms and may also reflect the burgeoning notion that distributed circuits -and nodes along these circuits -rather than discrete structures are the optimal substrates for stimulation [19] . Along these lines, it is important to note the critical role of imaging for preoperative planning, intraoperative guidance, and postoperative programming.
The growing number of clinical trials involving a neuroimaging component reflects this shift in clinical practice. Tractography and functional networks have been used to individualize targeting, accounting for slight anatomical variations in patients. Recent studies have also shown the value of intraoperative guidance, without the need for awake surgery [23, 24] . A detailed connectivity map that includes an individual's precise electrode location will be a useful tool to direct stimulation on intended structures and avoid stimulating adjacent areas. This would improve therapeutic outcomes while reducing stimulation-induced side effects [19] .
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Industry partnerships and funding dynamics play an important role in shaping the field of DBS research, especially in terms of driving innovation and technological advancements. The global market value of DBS devices was estimated at USD 664.4 million in 2015 and is projected to increase by 8.2% during the forecast period from 2016 to 2024 [25] . Several different companies manufacture DBS systems; some of these (e.g., Medtronic PLC) have existed for decades, while others have arisen following the FDA approval of DBS for movement disorders in the early 2000s. There are also some companies that are relatively new to the scene (e.g., SceneRay Corp., Ltd. and Beijing PINS Medical Co., Ltd.) [6] . Despite the emergence of several new DBS manufacturers over the past decades, Medtronic is still the most prominent manufacturer of devices used in clinical research. This has important implications, given that the availability and accessibility of hardware from different manufacturers influence the type of clinical work that is being done. For example, directional electrodes -currently produced only by Boston Scientific Corp. and Abbott Laboratories -permit programming optimization work that is otherwise not possible. Although not much detail was provided on studies' funding sources, a quarter of studies were explicitly stated to be industry-funded. This is less than what was reported for a representative sample of 200 clinical trials that addressed pharmacological and surgical interventions, whereby the most frequent funding sources were governmental (58%) and industry/private-for-profit (40%) [26] . To ensure transparency, standardized reporting of funding information is important at the time of publication and should include specification of the role of the funder. 17/25 An important limitation of this study is its reliance on the US-based clinical trials registry, ClinicalTrials.gov. Although this is the largest clinical trials database in the world, with over 230,000 trial registrations from 195 countries, it is run by the United States National Library of Medicine at the National Institutes of Health. Only trials conducted in or using materials produced in the US are mandated by the FDA to register with ClinicalTrials.gov. As such, this database is likely biased towards US-centric entries, which could account for the large difference in the total number of trials conducted between the US and the rest of the world. Nonetheless, peer-reviewed journals are increasingly moving toward adoption of the ICMJE policy that requires appropriate ClinicalTrials.gov registry as a prerequisite for publication, a move that appears to be driving increased registration of international studies [27] . 
Methodological limitations
